Supernus Pharmaceuticals, Inc.
Status: Publicly traded
Direct answer
Supernus Pharmaceuticals, Inc. is publicly traded on NASDAQ under the ticker SUPN.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed...
Can you invest in Supernus Pharmaceuticals, Inc.?
Yes. Supernus Pharmaceuticals, Inc. trades publicly on NASDAQ as SUPN.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Supernus Pharmaceuticals, Inc.
Detailed equity research is provided by MarketSnap.